<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878564</url>
  </required_header>
  <id_info>
    <org_study_id>UT-Schisto</org_study_id>
    <nct_id>NCT02878564</nct_id>
  </id_info>
  <brief_title>Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology</brief_title>
  <official_title>Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UVRI-IAVI HIV Vaccine Program, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the impact of Schistosoma mansoni infection and its
      treatment on genital immunology and HIV susceptibility in Ugandan women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schistosomiasis mansoni is a water-borne disease caused by helminth Schistosoma mansoni (S.
      mansoni), in which adult worms deposit eggs in mesenteric blood vessels. Schistomiasis
      prevalence in the fishing communities in East Africa, and particularly in the Lake Victoria
      region, exceeds 60% and there is overlap in this region with a high prevalence of HIV (29%).

      A recent epidemiological study found an association between S. mansoni and HIV infection in
      adult women residing near Lake Victoria in Tanzania. Furthermore, in primate studies S.
      mansoni infection was shown to increase susceptibility to SIV infection after rectal (but not
      intravenous) challenge, implying that S. mansoni might increase HIV susceptibility by
      altering local mucosal (gut) immunology.

      While S. mansoni does not directly infect the genital tract, we hypothesize that the
      inflammation it causes in the gut may be associated with mucosal inflammation at other sites
      through activation of common mucosal homing integrins such as a4b7. Therefore in this study
      we propose to explore whether S. mansoni increases inflammation and/or HIV susceptibility in
      the endocervix of adult women.

      HIV-uninfected adult women from Entebbe, Uganda will be screened for schistosomiasis using a
      commercial CCA rapid test kit, and infected women who fulfill the study eligibility criteria
      will be recruited into the study. Kato-Katz microscopy analysis will be performed to assess
      egg shedding at baseline. Additionally, urine microscopy will be done to screen for
      Schistosoma hematobium (which can directly involve the genital mucosa). Schistosomiasis
      treatment will be provided to all participants according to Ugandan clinical guidelines.

      Endocervical cytobrush, vaginal SoftCup and blood samples will be collected at three time
      points; at baseline and 4 and 8 weeks after schistosomiasis treatment, at the same stage of
      the menstrual cycle. Using an ex vivo HIV entry assay and mucosal cytokine and microbiome
      analyses we will quantify the effect of S. mansoni and its treatment on cervical HIV
      susceptibility and genital inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the percentage of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.</measure>
    <time_frame>1 month.</time_frame>
    <description>The percentage of endocervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct, as quantified by flow cytometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the number of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.</measure>
    <time_frame>1 month.</time_frame>
    <description>The number of endocervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct, as quantified by flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of blood CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.</measure>
    <time_frame>1 and 2 months.</time_frame>
    <description>The percentage of blood CD4+ T cells infected ex vivo by an HIV pseudovirus construct, as quantified by flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the phenotype of endocervical and blood CD4+ T cells after treatment of schistosomiasis.</measure>
    <time_frame>1 and 2 months.</time_frame>
    <description>Surface expression of CCR5, CD69, CD38, HLA-DR, a4b7, CCR7 and CD45RA by endocervical and blood CD4 T will be assessed using flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in genital proinflammatory cytokine levels after treatment of schistosomiasis.</measure>
    <time_frame>1 and 2 months.</time_frame>
    <description>A predefined genital inflammation score based on genital levels of pro-inflammatory cytokines and chemokines [as per Arnold K et al, Muc Immunol, 2015] will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the cervico-vaginal microbiome after treatment of schistosomiasis.</measure>
    <time_frame>1 and 2 months.</time_frame>
    <description>The cervico-vaginal microbiome will be assessed by 16s rRNA sequencing before and after schistosomiasis therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the cervico-vaginal proteome after treatment of schistosomiasis.</measure>
    <time_frame>1 and 2 months.</time_frame>
    <description>The genital proteome will be assessed by mass spectrometry before and after schistosomiasis therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.</measure>
    <time_frame>2 months.</time_frame>
    <description>The percentage of endocervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct, as quantified by flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.</measure>
    <time_frame>2 months.</time_frame>
    <description>The number of endocervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct, as quantified by flow cytometry.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Schistosomiasis Mansoni</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Praziquantel treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be HIV-uninfected women with asymptomatic Schistosoma mansoni infection; the study will examine the impact of standard praziquantel therapy (40 mg/kg po single dose) on genital immunology and HIV susceptibility.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Praziquantel</intervention_name>
    <description>40 mg/kg, PO (orally administered tablets)</description>
    <arm_group_label>Praziquantel treatment</arm_group_label>
    <other_name>Agopraz, bromoxel, biltricide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive (score above &quot;trace&quot;) on a urine CCA rapid test

          -  Willing to be treated with praziquantel

          -  Willing to give informed consent, and answer short questionnaires on economic status,
             and sexual risk behavior.

          -  Willing to comply with the requirements of the protocol

          -  HIV and classical STI (see below) negative

        Exclusion Criteria:

          -  HIV infected

          -  Malaria infected

          -  Pregnant.

          -  Irregular menstrual cycle, or actively menstruating at the time of genital sampling.

          -  Tested positive for classical STIs (syphilis, gonorrhea, chlamydia, Trichomonas
             vaginalis) or having genital ulcers

          -  Prior hysterectomy

          -  Deemed by physician to be unlikely to complete study protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupert Kaul, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UVRI-IAVI HIV Vaccine program</name>
      <address>
        <city>Entebbe</city>
        <state>Wakiso</state>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Arnold KB, Burgener A, Birse K, Romas L, Dunphy LJ, Shahabi K, Abou M, Westmacott GR, McCorrister S, Kwatampora J, Nyanga B, Kimani J, Masson L, Liebenberg LJ, Abdool Karim SS, Passmore JA, Lauffenburger DA, Kaul R, McKinnon LR. Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunol. 2016 Jan;9(1):194-205. doi: 10.1038/mi.2015.51. Epub 2015 Jun 24.</citation>
    <PMID>26104913</PMID>
  </reference>
  <reference>
    <citation>Downs JA, van Dam GJ, Changalucha JM, Corstjens PL, Peck RN, de Dood CJ, Bang H, Andreasen A, Kalluvya SE, van Lieshout L, Johnson WD Jr, Fitzgerald DW. Association of Schistosomiasis and HIV infection in Tanzania. Am J Trop Med Hyg. 2012 Nov;87(5):868-73. doi: 10.4269/ajtmh.2012.12-0395. Epub 2012 Oct 1.</citation>
    <PMID>23033399</PMID>
  </reference>
  <reference>
    <citation>Chenine AL, Shai-Kobiler E, Steele LN, Ong H, Augostini P, Song R, Lee SJ, Autissier P, Ruprecht RM, Secor WE. Acute Schistosoma mansoni infection increases susceptibility to systemic SHIV clade C infection in rhesus macaques after mucosal virus exposure. PLoS Negl Trop Dis. 2008 Jul 23;2(7):e265. doi: 10.1371/journal.pntd.0000265.</citation>
    <PMID>18648516</PMID>
  </reference>
  <reference>
    <citation>Joag VR, McKinnon LR, Liu J, Kidane ST, Yudin MH, Nyanga B, Kimwaki S, Besel KE, Obila JO, Huibner S, Oyugi JO, Arthos J, Anzala O, Kimani J, Ostrowski MA; Toronto HIV Research Group, Kaul R. Identification of preferential CD4+ T-cell targets for HIV infection in the cervix. Mucosal Immunol. 2016 Jan;9(1):1-12. doi: 10.1038/mi.2015.28. Epub 2015 Apr 15.</citation>
    <PMID>25872482</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Rupert Kaul</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Schistosomiasis mansoni</keyword>
  <keyword>HIV susceptibility</keyword>
  <keyword>Genital immunology</keyword>
  <keyword>Mucosal immunology</keyword>
  <keyword>HIV entry assay</keyword>
  <keyword>Adult women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Schistosomiasis</mesh_term>
    <mesh_term>Schistosomiasis mansoni</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

